| Abstract MO41 – Table 1. Summary of TANGO study outcomes at week 196. | ||||
|---|---|---|---|---|
| ES DTG/3TC | LS DTG/3TC | |||
| (N = 369) | (N = 298) | |||
| Parameter, n (%) | Day 1 to week 48 | Day 1 to week 144 | Day 1 to week 196 | Week 148 to week 196 |
| Efficacy outcomes (Snapshot, ITT‐E population) | ||||
| HIV‐1 RNA <50 copies/mL | 344 (93) | 317 (86) | 306 (83) | 278 (93) |
| HIV‐1 RNA ≥50 copies/mL | 1 (<1) | 1 (<1) | 3 (<1) | 0 (0) |
| No virologic data | 24 (7) | 51 (14) | 60 (16) | 20 (7) |
| Key safety outcomes (safety population) | ||||
| Any AE | 295 (80) | 336 (91) | 347 (94) | 239 (80) |
| AEs leading to withdrawal | 13 (4) | 23 (6) | 25 (7) | 9 (3) |
| Drug‐related grade 2 to 5 AEs | 17 (5) | 21 (6) | 23 (6) | 11 (4) |
| SAEs | 21 (6) | 57 (15) | 65 (18) | 15 (5) |
| Fatal AEs | 1 (<1) | 3 (<1) | 4 (1) | 0 (0) |
| Confirmed virologic withdrawals (all screened participants) | 0 (0) | 0 (0) | 1 (<1)a | 0 (0) |
AE, adverse event; DTG/3TC, dolutegravir/lamivudine; ES, Early‐Switch; LS, Late‐Switch; SAE, serious AE.
aNo resistance‐associated mutations were observed.